Biopharmaceutical company Poolbeg Pharma plc (AIM: POLB) disclosed on Monday that it has received formal notification that the Canadian patent office has granted its patent application covering POLB 001 for the prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS).

This patent covers the use of any p38 MAPK inhibitor, including POLB 001, in preventing CRS linked to cancer immunotherapies and is supported by proprietary data generated by the company. The Canadian approval follows a patent grant in Australia announced in March 2026 and represents the second national grant within Poolbeg's cancer immunotherapy-induced CRS patent family.

Poolbeg filed its initial oncology patent applications in the UK in January 2023 before entering the Patent Cooperation Treaty system in January 2024. The Canadian grant was accelerated under the Patent Prosecution Highway programme, which supports faster examination following favourable rulings in participating jurisdictions.

The company said the latest approval strengthens its international intellectual property portfolio across cancer immunotherapy-induced CRS and severe influenza, while enhancing the commercial value and partnering potential of POLB 001.

Poolbeg is focused on oncology and immunology therapies, including POLB 001 and an oral encapsulated GLP-1 treatment for obesity.